Dr. Joel Kahn dives into a groundbreaking Phase 1 trial of Verve 102, a one-time intravenous gene-editing treatment that silences the PCSK9 gene to produce lasting LDL cholesterol reduction. Among 35 participants, the high-dose group saw LDL drop by 62% with mostly mild side effects — promising results, though Phase 2 and 3 trials and 15 years of follow-up still lie ahead.
Also covered: updated colorectal cancer screening guidelines now starting at age 45, healthy lifestyle habits cutting mortality risk in cancer survivors by one-third, real-world weight regain data after stopping GLP-1 medications, why your B12 "normal" range may be too low, a blood test that may predict Alzheimer's years in advance, and a longevity preparedness tool from MIT AgeLab.
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Joel Kahn. Innehållet i podden är skapat av Dr. Joel Kahn och inte av,
eller tillsammans med, Poddtoppen.
